SCHEMBL25559540

SCHEMBL25559540

CCc1cnc(C(=O)O)nc1-c1ccc(C#N)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.41
▸ PPARD Q03181 1/20 0.41
▸ PPARA Q07869 1/20 0.41
▸ GRIA2 P42262 1/20 0.41
▸ GRIA4 P48058 1/20 0.41
▸ SLC22A12 Q96S37 4/20 0.40
▸ EGLN1 Q9GZT9 2/20 0.40
▸ MMP2 P08253 1/20 0.40
▸ PTGER4 P35408 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ PTGDR2 Q9Y5Y4 3/20 0.39
▸ CYP11B2 P19099 1/20 0.38
▸ FLT1 P17948 1/20 0.38
▸ EGLN3 Q9H6Z9 1/20 0.38
▸ HSD11B1 P28845 1/20 0.37
▸ CNR1 P21554 1/20 0.37
▸ CYP2A6 P11509 1/20 0.37
▸ PARP1 P09874 1/20 0.36
▸ PRKDC P78527 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30036156 0.83 PDK1 (0.45) SLC22A12EGLN1MMP2PTGER4MAP4K4
SCHEMBL25552017 0.83 PDK1 (0.45) SLC22A12EGLN1MMP2PTGER4MAP4K4
SCHEMBL25213116 0.81 KDM1A (0.44) SLC22A12EGLN1MMP2MAP4K4FLT1
SCHEMBL25560591 0.76 PDK1 (0.36) PTGDR2
SCHEMBL25561260 0.71 TGFBR1 (0.46) —
SCHEMBL25551902 0.71 DHODH (0.40) CNR1
SCHEMBL25565952 0.69 BAZ2B (0.44) CNR1
SCHEMBL30037043 0.69 PDK1 (0.43) EGLN1CYP11B2
SCHEMBL25552027 0.69 PDK1 (0.43) EGLN1CYP11B2
SCHEMBL25560272 0.69 PDK1 (0.43) SLC22A12EGLN1MMP2CYP11B2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 PPARG 1546/4885PPARD 2673/4885PPARA 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback